TGFB1 and type 2 diabetes mellitus: Metformin, the oral drug commonly used for type 2 diabetes mellitus (T2DM) therapy, has been found to improve the renal function and the related EMT/tubulointerstitial fibrosis via AMPK activation and TGF-β1 downregulation.